The objectives ofthe Development Research Program of the DF/HCC Kidney Cancer SPORE are 1) to provide short-term funding for innovative and meritorious research projects in kidney cancer that have the potential to evolve into translational studies, 2) to fund efforts that will complement or enhance the overall scope and quality of the SPORE and 3) to ensure a continual renewal of high quality and innovative translational research within the SPORE. These projects may be investigator-initiated laboratory or clinical research, or they may be designed to create a shared resource or enhance the research infrastructure of the SPORE. The Program will rely on the infrastructure created by the Administration, Evaluation and Planning Core (Core 1) to accomplish these goals. The process will involve: 1) Identification of promising areas of translational research related to kidney cancer 2) Solicitation of high quality applications addressing these and other areas 3) Selection of worthy projects for funding -Provision of critiques to selected projects -Provision of critiques, encouragement and support for potentially worthy, unselected projects 4) Provision of funds to the selected projects 5) Evaluation of progress and accomplishments ofthe projects including the possibility of 2nd year funding and transition into full project status 6) Evaluation of the success of the Developmental Program as a whole This process has served us well in the initial SPORE funding period with four Projects in the current grant application (Projects 1, 3, 4 and 5) being based in total or in part on scientific knowledge that emerged from Developmental Projects. Results of the first funding cycle are summarized below. The specific steps in this process are described in more detail thereafter.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
McDermott, David F; Cheng, Su-Chun; Signoretti, Sabina et al. (2015) The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21:561-8
Zerbini, Luiz Fernando; Bhasin, Manoj K; de Vasconcellos, Jaira F et al. (2014) Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther 13:1929-41
Akhavanfard, Sara; Vargas, Sara O; Han, Moonjoo et al. (2014) Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer 53:67-77
Bhatt, Rupal S; Atkins, Michael B (2014) Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res 20:2838-45
Choueiri, T K; Fay, A P; Gray, K P et al. (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25:2178-84
Panka, David J; Buchbinder, Elizabeth; Giobbie-Hurder, Anita et al. (2014) Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther 13:3210-8
Gubin, Matthew M; Zhang, Xiuli; Schuster, Heiko et al. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577-81
Wang, Xiaoen; Bullock, Andrea J; Zhang, Liang et al. (2014) The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol 7:188-95
Davis, Caleb F; Ricketts, Christopher J; Wang, Min et al. (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26:319-30
Choueiri, Toni K; Je, Youjin; Cho, Eunyoung (2014) Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer 134:384-96

Showing the most recent 10 out of 63 publications